Trends in Intrahepatic and Bile Duct Cancers in the United States from 1999 to 2023
-
By
-
Samuel W. Berg
-
Taylor Billion
-
Abubakar Tauseef
-
April 29, 2026
-
Clinical Scorecard: Trends in Intrahepatic and Bile Duct Cancers in the United States from 1999 to 2023
At a Glance
| Category | Detail |
|---|
| Condition | Liver and intrahepatic bile duct cancers |
| Key Mechanisms | Primarily arise from aberrant hepatocytes and bile duct tissue; hepatocellular carcinoma is the most common type. |
| Target Population | Adults aged 25 and older, with higher mortality in American Indian and Alaskan native populations. |
| Care Setting | Oncology and gastroenterology clinics, hospitals. |
Key Highlights
- Liver and intrahepatic bile duct cancers account for 4.9% of all cancer-related deaths.
- The 5-year relative survival rate for these cancers is only 21.7%.
- Mortality rates are higher in males compared to females.
- Intrahepatic bile duct cancers have increased incidence of 4.36% over the last decade.
- Geographic disparities exist, with the South and West regions having the highest mortality rates.
Guideline-Based Recommendations
Diagnosis
- Utilize endoscopic ultrasound (EUS), MRI Cholangiopancreatography (MRCP), PET/CT scans, and endoscopic brush cytology for diagnosis.
Management
- Focus on early detection and treatment strategies to improve outcomes.
Monitoring & Follow-up
- Regular screening for at-risk populations, particularly in high mortality regions.
Risks
- Higher mortality rates observed in American Indian and Alaskan native populations.
Patient & Prescribing Data
Adults aged 25 and older, particularly those with preexisting liver disease.
Late diagnosis often complicates treatment and eradication efforts.
Clinical Best Practices
- Encourage screening and diagnostic efforts in high-risk demographic groups.
- Implement population-level strategies to address disparities in mortality rates.
References
